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The use of anonymized stored tissue is a
routine practice in genetic research. Investigators who utilize stored samples are
neither required nor able to obtain informed consent before each use. Many genetic
studies, however, are conducted on specific
ethnic populations (e.g., Ashkenazi Jews).
The results in these cases, although individually anonymous, are not anonymous with
respect to the ethnicity of the participants.
This lack of group anonymity has led to
concern about the possibility of stigmatization and discrimination based on the results
of the genetic research. In the present study
we surveyed Jewish individuals about their
attitudes regarding the practice of using
stored DNA samples for genetic research.
Specifically, we were interested in whether
attitudes about informed consent and willingness to participate in genetics research
using stored DNA would depend on the
circumstances in which the material was
collected (i.e., clinical setting vs. research
setting) and the characteristics of the disease or trait under investigation. Overall,
most respondents reported that written
informed consent should be required and
that they would be willing to provide such
consent. Participants wt!!re most willing to
provide consent, however, when the sample
had been collected in a research rather than
clinical setting. Further, participants were
more likely to endorse the need for obtaining consent when the sample was collected
in a clinical setting. Finally, participants
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were significantly less willing to participate
in research that examined stereotypical or
potentially stigmatizing traits as opposed to
research that examined medical or mental
illnesses. Am. J. Med. Genet. 00: 000-000,
2001.

© 2001 Wiley-Liss, Inc.

KEY WORDS:

genetic testings; informed
consent

INTRODUCTION
Scientists' ability to evaluate disease susceptibility
has become increasingly refined over the last two
decades. In recent years, studies have provided evidence of alterations in some genes that indicate a
predisposition to breast cancer (BRCAl and BRCA2l.
These studies suggested that alterations in BRCAl
and BRCA2 occurred at a significantly higher rate in
Ashkenazi Jewish individuals (i.e., those of Eastern
European descent), as compared with the general population [Tonin et al., 1996; Hartge et al., 1999]. Many
Jewish individuals sought to participate in studies to
confirm those initial findings [Rothenberg, 1997]. This
was consistent with the community's successful collaboration with the researchers of Tay-Sachs disease in
the 1970s [Kaback et al., 1993; Kaplan, 1998].
After the BRCA1 and BRCA2 reports, another group
of investigators found a significantly higher prevalence
of a variant in a colorectal cancer susceptibility gene in
the Jewish population [Woodage et al., 1998]. When
this was reported in the media, however, some leaders
of the Jewish community advised Jews to avoid participating in further genetics research [Rothenberg and
Rutkin, 1998]. These advisors seemed to fear the discrimination or stigmatization of Jews as a consequence
of research identifYing the population as being at
higher risk for particular diseases [Rothenberg and
Rutkin, 1998].
In August of 1999, the National Bioethics Advisory
Committee (NBAC) recognized that concerns about
stigmatization were not unique to any one ethnic
community [NBAC, 1999]. This report, and others
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[King, 1992], underscored the point that genetics research has implications for families and social groups,
and that precautions are needed to minimize the social
risks to susceptible populations. The NBAC report also
urged caution in research involving the use of stored
biological materials when samples belong to individuals
or groups that are "socially or politically marginalized"
[National Bioethics Advisory Commission, 1999]. Other
reports have suggested that consultation with these
groups in the research development or reporting
phases, although not required by current regulations,
might help to minimize the social risks [Clayton, 1999].
Likewise, the National Institute of Health"s National
Human Genome Research Institute (NIH) has established as a research priority studies of how genetic
variation might interact with current concepts of race,
ethnicity, and culture [NIH, 1999].
The present report is the first empirical study on the
attitudes of Jewish individuals toward genetics
research involving the use of stored biological material
(DNA). The primary research question was whether
attitudes about informed consent and willingness to
participate in genetics research using stored DNA
would depend upon the circumstances in which the
material was collected (i.e., clinical settingvs. research
setting) and the characteristics of the disease under
investigation. Using hypothetical vignettes we designed
a survey to test the hypotheses that rates of willingness
to participate would be lower in the clinical vs. the
research setting. In addition, we predicted that willingness to participate would be highest for potentially
preventable medical diseases (e.g., heart disease), as compared with non preventable diseases (e.g., Huntington
disease) and mental illnesses (e.g., schizophrenia). We
further expected that willingness to participate would
be lowest for behavioral traits (e.g., anxiety), particularly those that might be stigmatizing (e.g., frugality).
Sociodemographic and cultural predictors of willingness to consent were also evaluated.

purchased list. The letters described the study and
mformed potential participants that they would be
contacted via telephone to participate in a survey. A
small gift (a telephone message board and marker) was
included with the introductory mailing. Two-weeks
after the first mailing, potential participants were contacted to complete a telephone survey. The structured
survey took about 30-min to complete and was administered by professional telephone interviewers using a
computer-assisted telephone interviewing system.

Description of the Survey
The survey instrument was designed to evaluate
attitudes toward genetics research using stored biological materials. The central characteristic of the survey
was the presentation of two hypothetical scenarios. The
first scenario described a situation in which the participant had provided an anonymous blood sample as
part of a research study to determine how common a
specific genetic mutation was in the Jewish population.
Later, a group of researchers requests to use his/her
blood for another research study on gene alterations
found in the Jewish community. The second scenario
was identical to the first except that the initial blood
sample was provided in a clinical setting (i.e., as part of
routine medical care) rather than as part of a research
study. In both scenarios, participants were assured
that their names could not be linked to the genetic
information and that the results could not be released
to insurance companies or employers.
.After each sc:enario, participants were presented
Wlth 8 hypothetical studies focusing on a gene related
to each of the following: 1) a medical illness that can
sometimes be prevented or treated if found early (e.g.,
heart disease); 2) a medical illness that presently
cannot be prevented or treated successfully (e.g.,
Huntington disease); 3) a mental illness (e.g., schizoph~enia~; 4) alcoholism; 5) frugality; 6) homosexuality;
7) mtell1gence; and 8) creativity.

MATERIALS AND METHODS
Participants
We recruited a group of Jewish men and women age
18 to 90 years. Introductory letters describing the study
were mailed to 1,800 individuals with Jewish surnames.
These individuals were identifi£d from a purchased list
of individuals with Jewish surnames in the BaltimoreWashington DC Metropolitan area. Of the 1,800 individuals to receive introductory letters, 217 (12%) no
longer resided at the listed address and 200 (11 %) were
found not to be Jewish. Thus, a total of 1,383 individuals were eligible to participate in the study. Of the
1,383 eligible individuals, 801 (58%) refused to participate in the survey and 308 (22%) could not be reached
after 10 attempts. Thus, the final sample consisted of
273 (20%) Jewish individuals who agreed to complete a
telephone survey.
Procedures

Introductory letters were mailed to each of the 1 800
individuals who were randomly selected from 'the
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Outcome Variables

Belief in the need for informed consent. For
each of the hypothetical studies above, participants were
asked to indicate whether they believed that written
consent should be required before re-using their DNA.
We calculated separate summary scores (ranging from 0
to 8) for the research and clinical scenarios by summing
the total number of affirmative responses for each.
Willingness to provide informed consent.
After each scenario, participants were asked whether
they would be willing to participate in each of the eight
hypothetical studies described above. We calculated
separate summary scores (ranging from 0 to 8) for the
research and clinical scenarios by summing the total
number of affirmative responses for each.

Predictor Variables

Socioclemographics. We assessed the following
soci~demographic

mantal status.

variables: age, education, gender,
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Jewish religious identity. Participants were
asked "How would you describe your religious identity?". Potential responses were classified as: orthodox,
conservative, reform, reconstructionist, secular, atheist/agnostic, don't know.
Jewish cultural identity. Participants were asked
to rate the strength of their Jewish cultural identity
using the following scale: not at all strong, moderately
strong, very strong. In subsequent analyses we divided
the sample into those who reported that their Jewish
identity was not at all strong/moderately strong
(N = 167) vs. very strong (N = 106).
Concerns regarding anti-Semitism. We assessed concerns about anti-Semitism with the following
questions: 1) how concerned are you about antiSemitism in the United States? and 2) how concerned
are you about the possibility that genetic information
about Jews might contribute to anti-Semitism?. These
questions were answered using a three-point Likert
scale ranging from 0 (not concerned at all) to 2 (very
concerned).
Attitudes toward community consent. We
assessed attit.udes toward community consent with the
following items: 1) in a genetics research study focusing
on the Jewish population, how important do you think
it is for researchers to consult with members of Jewish
religious and community organizations before initiating the study?; 2) how important is it for researchers to
get approval of Jewish religious and community
organizations before initiating the study?; 3) how important is it for you to be informed about any foreseeable risks to the Jewish community?; 4) how important
is it for you to be informed about any foreseeable
benefits to the Jewish community?
RESULTS
Sample Characteristics
Characteristics of the final sample are displayed in
Table I. Participants were equally divided between
men and women with a median age of 52. About twothirds of the individuals were married and more than
half had greater than a college education. In terms of
religious affiliation, all participants were Jewish with
about 10% reporting that they were orthodox, 28%
conservative, 41% reform or reeonstructionist, and 20%
secular, agnostic or atheist. Finally, 39% of the sample
reported that their Jewish cultural identity was very
strong.

Beliefs Regarding the Need for Consent
For both the research and clinical scenarios described
in the Methods section, participants were asked
whether they believed that researchers should obtain
written consent before using stored DNA in eight
hypothetical research studies designed to identify genes
associated with specific illnesses or traits. Figure 1
shows the proportion of participants who reported that
consent should be required for each of the specific tests
for each of the two scenarios. For each specific test, the
majority of participants (60-75%) believed that consent

TABLE I. Sociodemographic Characteristics
Variable

Levels

Age

Gender
Marital Status
Education
Religious affiliation

Jewish cultural identity

<40
::;50
50+
Male
Female
Married
Unmarried
< College Graduate
College Graduate
> College Graduate
Orthodox
Conservative
Reform/Reconstructionist
No affiliation (secular I
atheist/ agnostic)
Not at all strong
Moderately Strong
Very Strong

%

23
22
55
49

51
68
32
13
36

51
10
28
41
20
11
50

39

should be required regardless of whether the DNA was
collected in a research or clinical setting.
To compare the research vs. clinical scenario, we
created composite measures of belief in the need for
consent by summing the total number of affirmative
responses for each scenario. Scores on these composites
could range from 0 (meaning that the participants did
not believe consent should be required for any of the
tests) to 8 (meaning that consent should be required for
each of the illnesses/traits). We compared the composite consent scores for the research scenario (M = 5.1,
SD = 3.4) to those for the clinical scenario (M = 5. 7,
SD = 3.3) using a paired t-test. The results of this
analysis demonstrated an increased belief in the need
for consent when the samples were collected in a
clinical as compared to research setting (T(272) = 4.0,
P < 0.001). Chi-square comparisons of the individual
tests across scenarios revealed that for each of the eight
illnesses/traits, participants were more likely to
endorse the need for consent in the clinical as compared
to the research scenario (see Fig. 1).

Willingness to Participate
For both the clinical and research scenarios, participants were asked whether they personally would
consent to having their stored DNA used in these
studies. Figure 2 shows the proportion of participants
who reported that they would consent for each of the
illnesses/traits across the two scenarios. The willingness to consent to further testing was uniformly high
across both the clinical and research scenarios. There
was considerable variation, however, in the willingness
to consent between preventable/unpreventable disorders and those that might be considered stigmatizing.
To compare willingness to participate across the two
scenarios, we created composite measures of participation by summing the affirmative responses in each
scenario. The results of a paired t-test comparing the
research to clinical scenario, indicated that participants were more willing to participate in studies using
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DNA collected in the research setting (M = 6.4,
SD = 2.3) than the clinical setting (M = 6.1, SD = 2.7)
(T (272) = 2.5, P = 0.01). Chi-square comparisons across
the eight illness/traits revealed that willingness to
participate was higher for the research scenario for
studies of: untreatable medical illness, treatable medical illness, mental illness, alcoholism, creativity, and
intelligence. There was no difference across the two
scenarios in willingness to participate in studies of
homosexuality and frugality. These two traits had the

lowest levels of willingness to participate across the two
scenarios (see Fig. 2).

Impact of Study Characteristics on Need for
Consent and Willingness to Participate
To examine whether characteristics of the illness/
traits being studied impacted upon need for consent or
willingness to provide consent, we divided the illnesses/
traits into four categories: physical illness (treatable
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Fig. 3. The impact of test charscteristic on belief that consent is required. F (3,816) (= (5.18; P(= (0.0015. Bars with different letters differ significantly
(after Bonfcrroni correction).

and untreatable physical illness), mental/psychiatric
illness (mental illness, alcoholism), traits (intelligence,
creativity), and potentially stigmatizing/stereotype
confirming traits (frugality, homosexuality). We created
composite scores for each grouping by summing the
affirmative responses across the two scenarios (see Fig.
3). Repeated measures ANOVA across the four categories revealed significant differences in belief in the
need for consent (F(3,816) = 5.2, P = 0.002). Bonferroni
adjusted mean comparisons indicated that participants
believed that consent was more important when testing

A

Fig. 4.

for stigmatizing traits (M = 2.82, SD = 1.6) than when
testing for physical illness (M = 2.61, SD = 1. 7) or nonstigmatizing traits (M= 2.67, SD = 1.7).
As displayed in Figure 4, analysis using the composite scores on willingness to participate revealed a
statistically significant difference in willingness to
participate across the four categories {F(3,816l = 70.0,
P<O.OOl). Bonferroni corrected mean comparisons
revealed that participants were significantly less willing to participate in research designed to identify genes
associated with stigmatizing traits (M = 2.63, SD = 1.61)

Ill!

Impact oftest characteristics on willingness to participate. F (3,816) = 69.98; P < 0.0001. Bars without common letters differ significantly t..Ster

Bonferroni correction).
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ality or frugality, however, both of which are potentially
stigmatizing. We also explored participant characteristics that might influence attitudes about consent.
Individuals who were younger and had higher levels of
education were more likely to believe in the need for
Predictors of Consent and Participation
consent.
In exploratory analyses, we examined sociodemoIt is important to note that the participants in this
graphic (age, education level, marital status, sex), study represented a self-selected subset of those apattitudinal (concern about anti-Semitism, belief in proached for the survey (participation rate= 20%).
community consent) and religious (affiliation, Jewish This sample was made up of a high proportion of
cultural identity) variables as potential predictors of older individuals (more than half were above age 50).
consent and willingness to participate. The variables Further, this sample had an unusually high level of
that predicted consent were age (r=-0.20, P=0.01), education (over one half had Masters or Doctoral
education level (F(2,270) = 4.63, P = 0.01) and belief in degrees). It is not surprising that highly educated
community consent (r=0.13, P=0.04). Specifically, individuals might be strongly motivated to respond to
individuals who were under 50, those with college or a survey regarding genetics research. Because educapost-graduate degrees, and those who believed most tion level was positively associated with belief in
strongly in the need for community consent, reported the need for informed consent, however, it is possible
the strongest support for informed consent before the that this survey overestimated concerns about the
use of stored samples (across both scenarios). The only need for informed consent. Similarly, 39% of particivariable that predicted willingness to participate, was pants in this study reported that their Jewish culJewish cultural identity (t(269)=1.94, P=0.05). Spe- tural identity was very strong and 52% reported a
cifically, individuals with a stronger cultural identity moderately strong Jewish cultural identity. Again, it
were more willing to participate across scenarios and is not surprising that individuals who strongly identify
across illnesses/traits.
as Jewish would be particularly interested in participating in a study of attitudes toward genetics
research in the Jewish community. Because cultural
DISCUSSION
identity was positively related to willingness to partiThis descriptive study is the first to characterize the cipate in the hypothetical research scenarios, however,
attitudes of Jews regarding consent for use of stored this survey may have overestimated the wider Jewish
biological samples in different contexts. Overall, most community's willingness to participate in genetics
respondents reported that they believed that written research using stored samples. Clearly, the results of
informed consent should be required before reusing this study must be viewed as representing the attistored biological samples for genetics research. This tudes of a subset of the Jewish community, rather
was particularly true when the sample had been than the Jewish community at large or the general
acquired for clinical purposes, as compared with a population.
research setting. It is important to point out that we
In addition to this potential participation bias, a
did not assess belief in the need for verbal consent. It limitation of this study was that we did not provide
is likely that more participants would have endorsed specific information about the advantages and disthe requirement of verbal consent before reuse of the advantages of obtaining additional written consent
sample. An even larger proportion of respondents for re-use of biological specimens. Reports supporting
indicated that they would be willing to participate if the need for additional consent underscore the imporasked. Again, this was especially true for samples taken tance of individual autonomy in determining specific
in a research setting, as compared with a clinical sett- uses of stored samples, as well as the need to miniing. About 90% of respondents reported that they would mize the likelihood of stigmatization or discriminabe willing to provide consente for re-use of samples tion of particular individuals or groups [Rothenberg
collected in a research setting for studies of mental or and Rutkin, 1998; King, 1992]. The desire of some
physical disorders. Of course the stated willingness of participants for additional consent, however, must be
the study subjects to participate in the hypothetical balanced against the feasibility and costs of re-contactresearch, does not necessarily indicate that actual ing large numbers of participants, and the likelihood
participation would be that high. Previous research that incomplete capture of previous study participants
has demonstrated a relatively poor association between can result in biased study results. It is not known
stated intentions and actual behavior [Croyle and whether respondents were aware of these issues, or
Lerman, 1993].
· whether providing this information would have inftu.
One of the objectives of this study was to test the enced their attitudes about re-consent. Another limita·
hypothesis that there would be greater reluctance to ti,on of this study is that we did not provide information
provide consent for reuse of samples for conditions that about exactly what they had consented to in the
are potentially more stigmatizing. Contrary to expecta- original research study. Had the original consent been
tions, we did not find less willingness to participate in broad enough to cover experimental studies for a
studies of mental illness or behavioral traits. There was variety of physical illnesses, the need for additional
a small, but statistically significant, reduction in will- consent may not have been as widely endorsed. Also,
ingness to participate in studies involving homosexu- because our scenarios asked about consent for a study
than research to identify genes associated with medical
illness (M = 3.49, SD = 1.1), mental illness (M = 3.49,
SD = 1.1) or non-stigmatizingtraits (M = 2.94, SD = 1.6).
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on gene alterations in the Jewish population, it is not
known whether the same results would have been
obtained for genetics research not specifically targeted
toward Jews. It will be important in future studies to
learn how attitudes about consent are influenced when
additional details about the consent content and
process are provided.
Despite these limitations, the present study begins
to shed light on attitudes about consent for stored
biological samples among individuals in the Jewish
community. Although the views of our study respondents may not be representative of this community or
the general population at large, these results suggest
that some individuals feel strongly that additional
written consent should be required for re-use of
samples. Further, consent for participation in such
studies may depend, in part, on the specific condition to
be studied and the context in which the original sample
was obtained. Although not sufficient to inform policy
at this stage, these findings do raise questions that can
be addressed in future studies about the consent
content and process. Such studies will be valuable in
the development of policy on genetics research targeted
at population groups, that may present social implications for race, ethnicity or culture.
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